



- 437 World No-Tobacco Day—May 31, 2000
- 438 Prevalence of Cigarette Smoking Among Secondary School Students— Budapest, Hungary, 1995 and 1999
- 441 Costs of Smoking Among Active Duty U.S. Air Force Personnel—
 United States, 1997
- 445 Progress Toward Poliomyelitis Eradication—African Region, 1999–March 2000
- 449 Notice to Readers

World No-Tobacco Day — May 31, 2000

May 31 is World No-Tobacco Day (WNTD) 2000. This year's theme, "Entertainment and Tobacco Promotion—Countering the Deception," intends to raise awareness of the tobacco industry's global marketing practices and to mobilize action to counter the industry's recruitment of new customers through glamorizing tobacco use in films, music, art, and sports. Worldwide, tobacco use will cause an estimated 10 million deaths annually by 2030 (1). Each day, the tobacco industry must recruit 11,000 new users to replace smokers who die (2).

To build global support for tobacco-control measures, the World Health Organization (WHO) has developed the "Tobacco Kills—Don't Be Duped" media initiative. This effort

includes distribution of products with the "Bob" image (Figure 1), public service announcements featuring a super model and pop group, and a video with entertainers, artists, and sports figures endorsing antitobacco messages. Local and regional WNTD events will take place around the world, especially in countries where tobacco marketing remains largely unregulated.





Additional informa-

tion about World No-Tobacco Day 2000 is available at WHO's World-Wide Web site, http://www.who.int/toh/media/wntd2000/wntd2000.htm*, and at CDC's Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion site, http://www.cdc.gov/tobacco, or telephone (800) 232-1311. *References*

- World Health Organization. Combating the tobacco epidemic. In: World Health Organization's world health report 1999. Geneva, Switzerland: World Health Organization;1999:65–79.
- 2. World Health Organization. Tobacco kills—don't be duped. Available at: http://www.who.int/toh/media/wntd2000/posters.html. Accessed April 3, 2000.
- *References to sites of non-CDC organizations on the World-Wide Web are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

Prevalence of Cigarette Smoking Among Secondary School Students — Budapest, Hungary, 1995 and 1999

The average per capita cigarette consumption in Hungary is among the highest in the world (World Health Organization [WHO], unpublished data, 1997) (1). In 1999, the Metropolitan Institute of State Public Health and Public Health Officer Service, Budapest, Hungary, collaborating with CDC, conducted a survey of cigarette smoking among secondary school students aged 14–18 years in Budapest (1999 population of Budapest: approximately 2 million), similar to a survey conducted in 1995 (2). This report summarizes the survey findings, which indicate that current smoking among secondary school students in Budapest increased from 36% in 1995 to 46% in 1999.

The objective of the 1999 survey was to compare changes that had occurred since the 1995 survey in the prevalence of current* cigarette smoking, in the factors associated with current cigarette smoking, and in the smoking behaviors of current cigarette smokers (i.e., number of cigarettes smoked per day and number of days smoking occurred on school property). Among the 80,352 secondary school students in Budapest in 1999, 67,253 attended traditional high schools and 13,099 attended vocational/technical schools. Of 222 secondary schools (grades 9–12), 21 traditional high schools and nine vocational/technical schools were selected with a probability proportional to enrollment size. Classrooms in the 30 schools were selected randomly. All selected schools and classrooms agreed to participate, and all students in the selected classrooms were eligible to participate.

From March through May 1999, 2615 (85%) of 3092 eligible students† completed a pretested, standardized questionnaire that included questions about tobacco use translated from the U.S. Youth Risk Behavior Survey (3). Of the 2615 completed surveys, 2434 (93%) were from students aged 14–18 years; 24 (<1.0%) were age 14 years, a number too small for meaningful analysis. Therefore, analysis of data from 1999 was limited to students aged 15–18 years. The 1995 data for students aged 15–18 years were compared with 1999 data using Epi Info version 6.0. Prevalence odds ratios (POR)§ and 95% confidence intervals (CIs) were calculated using CSAMPLE to account for the complex survey design (4).

Among the 2410 students, 1148 (46.0%) (95% Cl=42.4%–49.5%) reported current smoking (Table 1). Prevalence of current smoking among male and female students was similar (44.9% and 46.9%, respectively) (POR=0.9; 95% Cl=0.8–1.1). Students aged 18 years were more likely to be current smokers than students aged 15 years (51.8% and 37.2%, respectively) (POR=1.8; 95% Cl=1.3–2.6). Prevalence of current smoking was higher among vocational/technical students than traditional high school students (60.2% and 43.1%, respectively) (POR=2.0; 95% Cl=1.5–2.6); among students whose friends smoked than those whose friends did not smoke (51.9% and 5.2%, respectively) (POR=19.5; 95% Cl=9.8–38.9); among students who reported that they had seen a teacher smoking during the school year than those who had not seen a teacher smoking (47.2% and 35.8%, respectively) (POR=1.6; 95% Cl=1.4–1.9); and among students with a family member who smoked than students whose family members did not smoke (51.9% and 36.6%, respectively) (POR=1.9; 95% Cl=1.5–2.3). The prevalence of current smoking was

^{*}Smoked on at least 1 day during the 30 days preceding the survey.

[†] 350 were absent; 127 refused to participate.

[§] Used to calculate odds ratios from cross-sectional data; an odds ratio from studies of prevalent rather than incident cases.

Cigarette Smoking Among Secondary School Students — Continued

TABLE 1. Number and percentage of current* smokers among secondary school students aged 15–18 years, by selected characteristics — Budapest, Hungary, 1995 and 1999

			Current smokers							
				1999		1995†				
Characteristic S	ample size⁵	No.	%	(95% CI [¶])	%	(95% CI)				
Sex										
Male	1181	558	44.9	(40.0-49.8)	36.7	(31.8–41.7)				
Female	1209	586	46.9	(43.2-50.6)	35.2	(30.1-40.3)				
Age (yrs)										
15	375	145	37.2	(28.5-45.9)	26.5	(21.7-31.3)				
16	664	295	43.0	(38.6-47.4)	35.5	(29.3-41.7)				
17	843	424	49.4 (45.9–52.9		39.4	(35.5-45.3)				
18	515	284	51.8	(47.3-56.3)	47.9	(42.1-53.6)				
Grade										
9	548	234	40.9	(33.0-48.8)	34.0	(28.5-39.7)				
10	764	366	45.5	(40.9-50.2)	32.8	(28.5-37.1)				
11	733	376	50.1	(45.3-54.8)	41.9	(36.6-47.2)				
12	333	159	47.2	(42.4-51.9)	36.1	(29.0-43.1)				
School type										
Vocational/Technical	680	409	60.2	(55.2-65.2)	54.2	(47.7-60.5)				
Traditional										
high school	1717	739	43.1	(39.0-47.3)	31.5	(27.1-36.0)				
Total	2410	1148	46.0	(42.4–49.5)	35.9	(32.0–39.8)				

^{*}Smoked a cigarette on at least 1 day of the preceding 30 days.

similar among students who discussed issues related to smoking and health in any of their classes and those who did not receive such instruction (44.8% and 48.6%, respectively) (POR=0.9; 95% Cl=0.7–1.1). Among students who were current smokers, 23.5% smoked \geq 11 cigarettes on the days that they smoked, 46.7% smoked daily, and 36.9% smoked on school property on \geq 10 days during the preceding month.

From 1995 to 1999, current smoking increased among female students (35.2% versus 46.9%), 17-year-old students (39.4% versus 49.4%), 10th graders (32.8% versus 45.5%), and traditional high school students (31.5% versus 43.1%). Although the prevalence of daily smoking was similar among male and female students in 1999 (46.2% and 46.4%, respectively), daily smoking among female students increased from 32% in 1995 while the rate for male students remained stable. The percentage of secondary school students in Budapest who smoked \geq 11 cigarettes per day during the preceding month increased from 1995 to 1999 (Table 2).

Reported by: É Kiss, MD, Div of Health Promotion and Protection; F Ferenczi, E Végh, MD, Dept of Child and Youth Health, Div of Health Promotion and Protection; K Lun, MD, Metropolitan Institute of State Public Health and Public Health Officer Svc, Budapest, Republic of Hungary. Epidemiology Br, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion; and an EIS Officer, CDC.

Editorial Note: The survey findings indicate that the prevalence of current cigarette smoking among secondary school students aged 15–18 years in Budapest increased

[†] Reference 2. The survey consists of 942 students who indicated that they were current smokers aged 15–18 years.

[§] For some characteristics, the sample size does not equal 2410 because of missing data.

[¶]Confidence interval.

Cigarette Smoking Among Secondary School Students — Continued

TABLE 2. Number and percentage of secondary school students aged 15–18 years who were current* smokers, by selected characteristics — Budapest, Hungary, 1995 and 1999[†]

			Current smokers							
		·	1999		1995§					
Characteristic	No.¶	(%)	(95%CI**)	(%)	(95%CI)					
No. cigarettes smoked per day										
1	205	19.8	(16.1-23.4)	22.9	(20.3-25.4)					
2–10	629	56.7	(52.8-60.7)	59.6	(56.1-63.1)					
≥11	294	23.5	(20.9-26.2)	17.5	(15.5-19.5)					
No. days used per month										
1–2	171	16.1	(12.9-19.3)	20.2	(18.0-22.4)					
3-9	158	14.6	(12.0-17.2)	14.7	(11.7–17.6)					
10–29	257	22.6	(20.2-25.0)	26.6	(22.9-30.4)					
≥30	562	46.7	(42.6-50.7)	38.5	(34.1-43.0)					
No. days used on school property										
per month										
0	459	43.2	(37.6-48.8)	48.6	(41.6-55.6)					
1–2	104	8.7	(6.5–10.9)	10.4	(8.5-12.2)					
3–9	143	11.2	(8.3-14.0)	11.1	(8.8–13.3)					
≥10	440	36.9	(33.4–40.5)	30.0	(23.9–36.1)					

^{*} Smoked a cigarette on at least 1 day of the preceding 30 days.

significantly from 1995 to 1999. In 1999, the prevalence of current smoking among adolescents aged 15 years was 37.2%. This finding is consistent with smoking rates among adolescents aged 13-15 years during 1999 in the Russian Federation, Moscow, where 33.4% were current smokers (5). The estimated 46% smoking prevalence for students in Budapest in 1999 is higher than the estimated 28.4% prevalence for U.S. high school students (grades 9-12) who participated in the 1999 National Youth Tobacco

In 1999, the Hungarian Parliament passed stronger legislation to enforce restrictions on smoking in the workplace and other public places. However, factors that may have contributed to the increased prevalence of smoking among youth in Budapest include a lack of regulation of the sale of cigarettes to minors until 1999 (T. Szilágyi, Health 21 Hungarian Foundation, personal communication, 2000), fewer advertising restrictions since 1997, free distribution of cigarette samples, weak health warnings, availability of contraband cigarettes, low fines for advertising violations, and lack of enforcement of existing regulations (1).

The findings in this report are subject to at least one important limitation. These data apply only to youth who attended secondary school and are not representative of all persons in this age group (e.g., secondary school students who dropped out and approximately 80% of gypsy children who do not attend secondary school) (7).

To better understand increasing prevalence rates of smoking among youth in Budapest and other central and eastern European countries, national health agencies must expand and evaluate tobacco prevention efforts and continue surveillance of trends in tobacco use among youth. The Global Youth Tobacco Survey (GYTS), sponsored by WHO's Tobacco Free Initiative (8) and CDC, will be conducted in Budapest by the end of

[§] Reference 2. The survey consisted of 942 students who indicated that they were current smokers aged 15–18 years.

¶ For each characteristic, the sample size does not equal 1148 because of missing data.

^{**}Confidence interval.

Cigarette Smoking Among Secondary School Students — Continued

2000 and throughout Hungary in 2001. GYTS will evaluate a wide range of variables, including knowledge and attitudes about tobacco, exposure to environmental tobacco smoke, familiarity with prosmoking and antismoking media messages, and exposure to tobacco-use prevention curricula in schools. These efforts, along with Hungary's development of a plan for tobacco control as part of the Framework Convention on Tobacco Control (8), are important steps in curbing the increase in smoking among secondary school students in Hungary.

References

- 1. World Tobacco Marketfile. Emerging markets in central and eastern Europe. Available at http://www.marketfile.co.uk/tobacco. Accessed March 2000.
- 2. CDC. Prevalence of cigarette smoking among secondary school students—Budapest, Hungary, 1995. MMWR 1997;46:56–9.
- 3. CDC. Youth risk behavior survey—United States, 1997. MMWR 1998;47(no. SS-3).
- 4. Dean AG, Dean JA, Coulombier D, et al. Epi Info, version 6: a word processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1996.
- 5. Canadian Public Health Association. Tobacco, smoking and youth. CPHA Health Digest April 1999;23:1–8.
- 6. CDC. Tobacco use among middle and high school students—United States, 1999. MMWR 2000;49:49–53.
- 7. Kézdi G. Secondary school education of Roma youngsters. In: Hungarian Academy of Sciences, ed. Gypsies in Hungary. Budapest, Hungary: Hungarian Academy of Sciences, 1999.
- 8. World Health Organization. The world health report 1999—making a difference. Combating the tobacco epidemic. Geneva, Switzerland: World Health Organization, 1999.

Costs of Smoking Among Active Duty U.S. Air Force Personnel — United States, 1997

Smoking is the leading cause of preventable disease and death in the United States (1). The health consequences of smoking impose a substantial economic toll on persons, employers, and society. Smoking accounts for \$50–\$73 billion in annual medical-care expenditures, or 6%–12% of all U.S. medical costs (2–5). The costs associated with lost productivity also are extensive (2). In 1997, approximately 25% of male and 27% of female active duty Air Force (ADAF) personnel aged 17–64 years were smokers (6). A 1997 retrospective cohort study was conducted among ADAF personnel to estimate the short-term medical and lost productivity costs of current smoking to the U.S. Air Force (USAF). This report summarizes the results of the study, which indicate that current smoking costs the USAF approximately \$107.2 million per year: \$20 million from medical-care expenditures and \$87 million from lost workdays.

Study participants completed a health assessment survey and were followed for 1 year; then researchers calculated participants' use of medical care and health-related lost work time (i.e., time spent on smoke breaks, days spent in the hospital, and time away from duty station for outpatient clinic visits). Total expenditures among current smokers and never smokers were used to compute population-attributable fractions (PAFs) (i.e., the fraction of expenditures attributable to ADAF members who currently smoked). Data were collected from 5164 active duty TRICARE Prime enrollees aged 17–64 years in Arkansas, Louisiana, Oklahoma, and Texas who completed the Health

Enrollment Assessment Review (HEAR) survey during September-December 1996, and who remained enrolled in the health plan the year following the HEAR survey. The HEAR instrument is a voluntary survey given to all TRICARE Prime enrollees. Self-reported demographic data were obtained by written questionnaires from the Air Force personnel system; smoking status, weekly alcohol consumption, frequency of aerobic exercise, and body mass index data also were obtained through self-administered questionnaires from HEAR (Table 1) (7). Respondents were classified as current, former, or never smokers*. Results for former smokers were not included in this study. Inpatient and outpatient visits, clinical diagnoses, bed days, and encounter costs were obtained from the Corporate Executive Information System (CEIS) and the TRICARE Management Activity. Prevalence estimates of all currently smoking ADAF personnel during 1997 were based on a linear interpolation of results from the 1995 and 1998 U.S. Department of Defense (DoD) Survey of Health Related Behaviors Among Military Personnel (6–8). Prevalence estimates in the DoD survey were 22% and 49% higher than HEAR among men and women, respectively. The DoD survey of risk behaviors is anonymous and is assumed to reflect current smoking in the ADAF population more accurately than the HEAR survey, which is not anonymous.

TABLE 1. Characteristics of study cohort and all active duty Air Force (ADAF) personnel and current smoking-attributable costs among ADAF personnel — United States, 1997*

		<u>Vlen</u>	W	omen	
Characteristic	Cohort	All	Cohort	All	ADAF
Age (yrs)†	31.9	30.4	30.9	28.2	
Race					
White	70.5%	78.4%	62.1%	67.7%	
Black	12.2%	13.5%	18.0%	22.8%	
Other [§]	17.3%	8.1%	19.9%	9.5%	
Current smoker	20.9%	25.5%	18.0%	26.8%	
Type of cost¶					
Smoking-attributable)				
direct medical cost	S	\$18,442,979		\$1,655,360	\$20,098,339
Smoking-attributable	•				
expenditures		7.7%		1.5%	5.8%
Smoking-attributable)				
productivity** cost	ts	\$75,989,629		\$11,153,087	\$87,142,716
Lost FTEs*		2,957		615	3,573

^{*} Age and race data for all ADAF personnel supplied by Air Force Personnel Center, Randolph Air Force Base, Texas.

^{*}HEAR defined current smokers as those who, at the time of the interview, smoked cigarettes every day or some days, and former smokers as those who currently did not smoke but had smoked in the past.

[†] The DoD survey defined current smokers as those who had smoked ≥100 cigarettes during their lifetime and smoked within the 30 days preceding the survey, former smokers as those who had smoked ≥100 cigarettes during their lifetime but had not smoked within the 30 days preceding the survey, and never smokers as those who had smoked <100 cigarettes during their lifetime.

[†] Mean

[§]Includes Hispanics, Asians/Pacific Islanders, and American Indians/Alaska Natives.

[¶]Based on 1995 and 1998 ADAF estimates from the U.S. Department of Defense Survey of Health Related Behaviors Among Military Personnel.

^{**}Time lost spent on breaks, days spent in the hospital, and time away from duty station for outpatient clinic visits.

[#] Full-time equivalents (i.e., the amount of time worked by one ADAF member in 1 year).

An empirical model was used to compare medical-care expenditures and lost work time among current smokers and never smokers. Men and women were modeled separately because of the influence of pregnancy-related events. A log-linear Poisson regression model was used to compare the rates of accumulating medical-care costs. Sexspecific rate ratios (RRs) were adjusted for age, race, weekly alcohol consumption, frequency of aerobic exercise, and body mass index. Adjusted RRs from HEAR were combined with current smoking prevalence data from the DoD survey to estimate PAFs of expenditures associated with current smoking for all ADAF personnel. The use of two distinct datasets in the PAF formula precluded computing confidence intervals (Cls). The average margin of error (one half the width of the CI around the mean) was ±3.6% for the RR estimates and ±4.1% for the prevalence estimates. The RR margins of error and smoking prevalence estimates indicate the overall stability of the PAFs. Smoking-attributable expenditures (SAEs) among men and women were calculated by multiplying the PAFs by total medical-care costs for each sex. Total medical-care costs for all ADAF personnel were \$347 million and were estimated by using CEIS data to extrapolate the sex-specific medical-care costs for the study cohort to the entire ADAF population. Productivity costs were estimated using 1996 age-specific and sex-specific salary and benefit data among ADAF personnel. Hospital days, outpatient clinic visit time, and excess break time for current smokers were included; nonhospital sick days were excluded.

Smoking-attributable medical-care costs for ADAF personnel were approximately \$20 million (Table 1), representing approximately 6% of the total annual Air Force medical system expenditures. In 1997, current smoking was associated with 893,128 lost workdays: 739,374 among men and 153,755 among women. Assuming 250 workdays per year, this lost work time represents a loss of approximately 3573 full-time equivalent positions (FTEs) in 1997: 2957 among men and 615 among women. Lost workdays represent approximately \$87 million in annual productivity losses: \$76 million among men and \$11 million among women.

Reported by: AS Robbins, MD, SY Chao, MS, GA Coil, MPH, VP Fonseca, MD, Office for Prevention and Health Svcs Assessment, Air Force Medical Operations Agency, Brooks Air Force Base, Texas. Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note: Current smoking among ADAF personnel is associated with large medical expenditures and lost productivity each year, particularly among men. The 6% SAF of medical expenditures is within the 6%–12% range of recent SAF estimates of total U.S. medical costs (2–5). DoD estimated that current smoking among all U.S. military health system beneficiaries cost the DoD an estimated \$930 million in 1995: \$584 million in annual health care expenditures and \$346 million in lost productivity (9). Among ADAF personnel, smoking-attributable productivity losses were more than four times the cost of medical care: 6.7 times among women and 4.1 times among men. The number of lost FTEs is larger than the number of FTEs on active duty at 35 (40%) of 87 USAF installations.

The findings in this report differ from previous cost-of-smoking estimates because the study population in this report excludes persons aged ≥65 years; the costs for former smokers were excluded. Consequently, medical costs among this younger population are a much smaller percentage of total smoking-attributable costs than in other studies (2,3). The exclusion of results for former smokers also lowers the costs of smoking estimates for women compared with men. Pregnancy-related events were a large portion of health-care use among ADAF women. Because a substantial proportion of women

quit smoking during pregnancy and many others conceal their smoking status during pregnancy (10), the SAEs PAFs among women who are classified as current smokers may be artificially low; this may account for the lower costs of smoking for women relative to men. In 1993, smoking-attributable medical costs for the United States were approximately 51% lower for women than men (4).

The findings in this report are subject to at least four limitations. First, the study cohort may not be representative of all ADAF personnel. Second, study participants knew their HEAR survey responses would become part of their medical record. This might have reduced the rate of self-reported smoking and other risk behaviors when compared with anonymous ADAF surveys (6–8); however, anonymity may be only one factor influencing differences in reported risk behaviors. Third, the medical-care costs and productivity losses of former smokers were not included. Finally, the study excluded lost productivity on days that ADAF personnel were on convalescent leave or confined to quarters; a large number of work days may have been missed because of less severe illnesses that did not require hospitalization. Limitations two, three, and four may underestimate the costs of smoking among ADAF personnel.

These results support USAF and DoD efforts to decrease the prevalence of smoking among ADAF personnel. Smoking-attributable lost work time is particularly important for USAF operational commanders because it adversely affects military readiness; however, the impact of smoking on productivity also is relevant to civilian employers. The prevalence of smoking among ADAF members is approximately the same as among the U.S. population aged 18–64 years (1). However, because of physical training requirements, smokers in the ADAF population are probably healthier than smokers in the civilian population. If so, average productivity losses to civilian employers could be larger than those found in this military group. Costs related to tobacco use are largely preventable. Implementing comprehensive tobacco-control programs remains an effective way to reduce associated medical and productivity losses.

References

- 1. CDC. Tobacco use-United States, 1900-1999. MMWR 1999;48:986-93.
- 2. Rice DP, Hodgson TA, Sinsheimer P, Browner W, Kopstein AN. The economic costs of the health effects of smoking, 1984. Milbank Q 1986;64:489–547.
- 3. CDC. Medical-care expenditures attributable to cigarette smoking—United States, 1993. MMWR 1994;43:469–72.
- 4. Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. Soc Sci Med 1999;48:375–91.
- 5. Miller LS, Zhang X, Rice DP, Max W. State estimates of total medical expenditures attributable to cigarette smoking, 1993. Public Health Reports 1998;113:447–58.
- 6. Bray RM, Sanchez RP, Ornstein ML, et al. 1998 Department of Defense Survey of Health Related Behaviors Among Military Personnel. Research Triangle Park, North Carolina: Research Triangle Institute, 1999.
- US Air Force Office for Prevention and Health Services Assessment. Health Enrollment Assessment Review 1.0 (HEAR) High Resource Utilization (HRU) Validation Study: final report. Washington, DC: Report for the Air Force Medical Operations Agency, January 1999.
- 8. Bray RM, Kroutil LA, Wheeless SC, et al. 1995 Department of Defense Survey of Health Related Behaviors Among Military Personnel. Research Triangle Park, North Carolina: Research Triangle Institute, 1995.
- 9. Helyer AJ, Brehm WT, Perino L. Economic consequences of tobacco use for the Department of Defense, 1995. Mil Med 1998;163:217–21.

10. Kendrick JS, Zahniser SC, Miller N, et al. Integrating smoking cessation into routine public prenatal care: the smoking cessation in pregnancy project. Am J Public Health 1995;85:217–22.

Progress Toward Poliomyelitis Eradication — African Region, 1999–March 2000

In 1988, the World Health Assembly resolved to eradicate poliomyelitis globally by 2000 (1). The African Region (AFR) of the World Health Organization (WHO) began implementing polio eradication strategies in 1996, including National Immunization Days (NIDs*) and acute flaccid paralysis (AFP) surveillance (2,3). This report summarizes progress toward polio eradication in AFR during 1999–March 2000, and suggests that although substantial progress has been reported toward interrupting poliovirus transmission in eastern and southern Africa, poliovirus remains endemic in other African countries in west and central Africa, especially among those experiencing internal strife or civil war.

Routine vaccination

AFR includes 48 countries and territories and is divided geographically into five major epidemiologic blocks: eastern, western, southern, central, and countries in special situations. Reported regional coverage with three doses of oral poliovirus vaccine (OPV3) among children aged 1 year was approximately 55% in 1999 and has remained relatively stable since 1990. OPV3 coverage by country ranged from 65%–75% in the eastern and southern blocks, 50%–55% in the western block, and approximately 40% in the central block. Coverage was lower (approximately 30%) among countries in difficult circumstances (e.g., Angola, Democratic Republic of Congo [DR Congo], and Ethiopia).

Supplemental vaccination

From January 1999 through March 2000, two or more rounds of NIDs or Subnational Immunization Days (SNIDs) were conducted in all 35 (73%) countries and territories of the region where polio is either endemic (20 countries) or was considered endemic until recently (15). An estimated 133 million children received at least two supplemental doses of OPV during 1999, representing a 50% increase over the number of children reached in similar campaigns in 1998. NIDs coverage was reported to be >80% in all countries, with the exception of Sierra Leone (76%) and Congo Brazzaville (55%). Countries conducting SNIDs (predominantly eastern and southern block countries) reported coverage >80%.

To accelerate progress toward eradication, intensified NIDs were conducted in nine countries in the region (Angola, Benin, Chad, DR Congo, Guinea-Bissau, Liberia, Niger, Nigeria, and Sierra Leone) during 1999. Intensified NIDs consisted of either additional rounds or administering the vaccine house-to house. DR Congo conducted three rounds of NIDs during July–September 1999 and reported coverage rates of 81%, 91%, and 80% for the first, second, and third rounds, respectively (4). Nigeria targeted 13 million children residing in 15 (35%) of 37 states during April–May 1999; all OPV doses were

^{*}Nationwide mass campaigns over a short period (days to weeks), in which two doses of oral poliovirus vaccine are administered to all children in the target age group (usually aged <5 years), regardless of vaccination history, with an interval of 4–6 weeks between doses.

administered in house-to-house vaccination campaigns. This effort reached 10%–40% more children in each state than had been reported from previous NID rounds (5). SNIDs also were conducted in the capitals of Central African Republic (Bangui) and Burkina Faso (Ouagadougou) in May and June 1999.

AFP surveillance

AFP surveillance improved rapidly in AFR during 1999; 4999 AFP cases were reported in 1999 compared with 1754 in 1998, an increase of nearly 200%. The nonpolio AFP rate more than doubled from 0.3 cases per 100,000 children aged <15 years in 1998 to 0.8 in 1999 (target: ≥1 nonpolio AFP case per 100,000 population aged <15 years) (Table 1). However, the proportion of AFP cases with two stool specimens collected within 14 days of onset of paralysis declined from 35% in 1998 to 31% in 1999. Of the 15 polio laboratories in the region, 13 were accredited during 1999, and all stool specimens were processed in accredited network laboratories.

Impact on poliovirus transmission

In 1999, wild poliovirus was isolated from 238 AFP case-patients residing in 16 AFR countries, mainly in central and western Africa and Angola (Figure 1). Angola experienced the largest polio outbreak ever recorded in Africa with 1093 cases and 89 deaths

FIGURE 1. Reported wild poliovirus — African Region, World Health Organization, 1999




TABLE 1. Performance indicators for acute flaccid paralysis (AFP) surveillance, by country — African Region, World Health Organization, 1998 and 1999

		199	8		1999						
			%				%				
Block/	No.	Nonpolio	Cases with adequate	Confirmed polio	No.	Nonpolio		n Confirmed polio			
Country	AFP cases			s⁺(Wild virus)	AFP cases	AFP rate	specimens	(Wild virus)			
Central											
Cameroon	40	0.4	60%	16 (0)	95	1.5	74%	1 (1)			
C. African		• • •	33,5	(0,			, 1,0	. (.,			
Republic	59	3.3	41%	6 (2)	38	1.3	43%	18 (1)			
Chad	12	0.3	83%	4 (4)	156	1.6	38%	109 (35)			
Congo	0				11	0.8	100%	2 (0)			
Equitorial Gu	uinea 0				1	0.0	0	1 (0)			
Gabon	1	0.2	100%	0 (0)	2	0.3	50%	0 (0)			
Western											
Algeria	88	0.8	75%	0 (0)	78	0.5	47%	10 (0)			
Benin	15	0.3	67%	8 (3)	71	1.4	42%	37 (8)			
Burkina Faso		0.1	50%	8 (4)	53	0.9	26%	5 (0)			
Gambia	0			- \ - /	0	0.0	0	0 (0)			
Ghana	154	0.5	30%	112 (18)	114	1.4	50%	3 (3)			
Guinea	7	0.1	43%	4 (0)	51	0.9	43%	22 (3)			
Guinea-Bissa	au 0				0	0.0	0	0 (0)			
Cotê d'Ivoire	9 71	0.4	42%	38 (11)	144	1.8	60%	9 (9)			
Liberia	0				75	2.4	36%	42 (11)			
Mali	23	0.2	30%	14 (2)	43	0.4	51%	22 (4)			
Mauritania	0				13	0.6	31%	6 (0)			
Niger	12	0.1	50%	8 (4)	110	1.1	44%	56 (10)			
Senegal	17	0.2	39%	10 (2)	65	1.5	58%	0 (0)			
Sierra Leone	3	<0.1	0	3 (0)	24	0.5	33%	14 (2)			
Togo	10	0.2	60%	5 (1)	36	1.5	58%	1 (1)			
Southern											
Botswana	5	0.7	80%	0 (0)	11	1.6	45%	0 (0)			
Lesotho	5	0.2	40%	3 (0)	12	1.3	75%	0 (0)			
Madagascar	17	0.2	53%	6 (0)	28	0.4	52%	0 (0)			
Malawi	28	0.5	79%	5 (0)	22	0.4	73%	0 (0)			
Mozambique	16	0.1	56%	7 (0)	32	0.4	22%	0 (0)			
Namibia [.]	11	1.3	64%	2 (0)	16	1.9	6%	3 (0)			
South Africa	167	0.4	13%	104 (0)	147	1.0	29%	4 (0)			
Swaziland	5	1.3	60%	0 (0)	5	1.3	80%	0 (0)			
Zimbabwe	51	0.7	43%	17 (0)	57	1.1	42%	2 (0)			
Eastern											
Burundi	0				16	0.5	94%	1 (0)			
Eritrea	0				12	0.3	38%	7 (0)			
Kenya	123	0.1	8%	109 (0)	270	0.8	41%	63 (0)			
Rwanda	2	0.1	0	2 (0)	45	0.5	38%	28 (0)			
Tanzania	127	0.4	48%	66 (0)	199	1.3	71%	0 (0)			
Uganda	61	0.1	23%	46 (0)	187	1.8	49%	0 (0)			
Zambia	23	0.4	39%	6 (0)	68	0.8	41%	30 (0)			
Special Situati	ion										
Angola	16	0.1	56%	7 (3)	1176	1.2	7%	1103 (53)			
DR Congo	21	0.1	52%	10 (0)	84	0.2	43%	45 (1)			
Ethiopia	63	0.1	13%	55 (0)	189	0.2	24%	132 (1)			
Nigeria	489	0.4	39%	312 (42)	1242	0.5	26%	981 (95)			
Total	1754	0.3	39%	993 (96)	4999	0.8	31%	2856 (238)			

^{*} Per 100,000 children aged <15 years.

[†] Two stool specimens collected at an interval of at least 24 hours within 14 days of onset of paralysis and adequately shipped to the laboratory.

(6). Wild poliovirus circulation was detected in stool specimens from AFP cases in Nigeria (95), Angola (53), Chad (35), Liberia (11), Niger (10), Cotê d'Ivoire (nine), and Benin (eight). Wild poliovirus also was detected in Cameroon, Central African Republic, DR Congo, Ethiopia, Ghana, Guinea, Mali, Sierra Leone, and Togo. No wild poliovirus was detected in southern Africa.

Reported by: Expanded Program on Immunization, World Health Organization Regional Office for Africa, Harare, Zimbabwe; Vaccines and Biologicals Div, World Health Organization, Geneva, Switzerland. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Vaccine Preventable Disease Eradication Div, National Immunization Program, CDC.

Editorial Note: Intensified efforts to achieve polio eradication were implemented in the remaining countries of AFR where polio is endemic during 1999. Specific actions to improve the quality of supplemental vaccination campaigns (NIDs and SNIDs) included 1) intensified NIDs using the house-to-house strategy; 2) increased provision of technical assistance (e.g., logisticians, epidemiologists, and social mobilization experts); 3) dissemination of guidelines to achieve quality NIDs; and 4) synchronization of NIDs among countries having contiguous borders, including special cross-border coordination strategies. In addition, SNIDs were implemented in at least two countries, and special attention was given to improving the quality and geographic coverage of AFP surveillance.

Serious constraints to improving the quality and the geographic coverage of NIDs persisted in 1999. Wars, civil unrest, and political instability made it impossible to reach all unvaccinated children in certain countries during NIDs (Angola, Congo Brazzaville, DR Congo, Nigeria, and Sierra Leone). In October and November of 1999, the global shortfall in the OPV supply made it necessary to postpone NIDs in Burknia Faso, Chad, Ghana, Kenya, Niger, Sierra Leone, and Togo. In addition, some countries received OPV without vaccine vial monitors.

Although AFP surveillance has improved substantially from 1998 to 1999, further improvements are needed to increase the nonpolio AFP rate from 0.8 to the standard threshold of ≥1.0, indicating a sensitive surveillance system. The stool collection rate remains low in AFR. Although some of the decrease in the collection rate during 1998–1999 may be because not all cases associated with the 1999 Angola outbreak needed to be virologically confirmed, stool collection rates in the region did not increase in 1999.

Wild poliovirus is assumed to circulate in Sierra Leone and Congo Brazzaville, but surveillance was not operating for most of 1999 in these countries. In addition, the quality of surveillance is inadequate to determine whether wild poliovirus transmission continues in Madagascar, Malawi, and Mozambique. These three countries have low routine vaccination coverage and no longer conduct supplementary vaccination activities.

Efforts to improve the quality of AFP surveillance in 1999 and early 2000 include 1) increased funding for AFP surveillance; 2) expansion of active surveillance to the provincial level; and 3) provision of additional technical support for AFP surveillance through the Stop Transmission of Polio (STOP) Initiative in Chad, DR Congo, Ghana, Guinea, Kenya, Niger, Nigeria, and Uganda.

Although indigenous wild poliovirus is virtually absent in southern and eastern Africa and wild poliovirus circulation has declined to low levels in the some parts of west Africa, countries with intense circulation of wild poliovirus, including Angola, Chad, DR Congo, Ethiopia, Nigeria, and Sierra Leone, pose a risk for delaying global polio eradication. The remaining major challenges to polio eradication in AFR are 1) conducting high-quality

supplemental vaccination activities and additional rounds and mopping-up activities where indicated, with emphasis on reaching previously unvaccinated children; 2) gaining access to all children in countries affected by conflict (e.g., Angola, Congo Brazzaville, DR Congo, and Sierra Leone); 3) assuring adequate quantities of potent OPV vaccines for routine and supplemental vaccination activities; 4) addressing basic routine EPI infrastructure in Angola, DR Congo, Liberia, Nigeria, and Sierra Leone; 5) filling the shortfall in funding[†] for polio eradication in AFR; and 6) rapidly improving the quality of AFP surveillance.

References

- 1. World Health Assembly. Global eradication of poliomyelitis by the year 2000: resolution of the 41st World Health Assembly. Geneva, Switzerland: World Health Organization, 1988 (Resolution WHA 41.28).
- Regional Committee for Africa. Expanded Program on Immunization: disease control goals, the countdown has started—resolutions of the 45th Regional Committee for Africa. Brazzaville, Congo: World Health Organization, 1995 (Resolution AFR/RC45/R5).
- 3. Organization of African Unity. Yaounde declaration on polio eradication in Africa. In: Proceedings of the 32nd Ordinary Session of the Organization of African Unity meeting. Yaounde, Cameroon: Organization of African Unity, 1996 (AHG/Declaration 1 [XXXII]).
- 4. CDC. Progress toward poliomyelitis eradication—Democratic Republic of Congo, 1996–1999. MMWR 2000;49:253–8.
- 5. CDC. Progress toward poliomyelitis eradication—Nigeria, 1996–1998. MMWR 1999;48: 312–6.
- 6. Valente F, Otten M, Balbina F, et al. Massive outbreak of poliomyelitis caused by type-3 wild poliovirus in Angola in 1999. Bull WHO 2000;78:339–46.


Notice to Readers

Satellite Broadcast on Preparing for the Next Influenza Pandemic

A Public Health Training Network (PHTN) satellite broadcast titled "Update: Preparing for the Next Influenza Pandemic," is scheduled for July 13, 2000, from 9 to 11 a.m. and rebroadcast from 1 to 3 p.m. eastern time. This broadcast will update local, state, and national plans; describe the integration of local, state, and federal partners in pandemic influenza planning; and describe roles for antiviral drug use and triage and infection control measures. Additional information is available on the World-Wide Web at http://www.cdc.gov/phtn/pandemic/pandemicflu.htm, by telephone at (404) 639-8799, or by e-mail at cwilkins@cdc.gov. This program is a production of the PHTN and CDC's National Immunization Program and National Vaccine Program Office.

[†] The polio eradication initiative in AFR is supported by AFR member countries. External funding is provided by Rotary International, United Nations Childrens' Fund, the governments of Canada, United States, United Kingdom, Norway, and Belgium, the United Nations Foundation, the Gates Foundation, the De Beers Corporation, WHO, and CDC.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending May 20, 2000, with historical data



^{*}Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending May 20, 2000 (20th Week)

		Cum. 2000		Cum. 2000
Anthrax		_	HIV infection, pediatric*§	85
Brucellosis*		15	Plaque	2
Cholera			Poliomyelitis, paralytic	
	bella syndrome	4	Psittacosis*	5
Cyclosporiasis		6	Rabies, human	_
Diphtheria		1 -	Rocky Mountain spotted fever (RMSF)	52
Encephalitis:	California serogroup viral*	2	Streptococcal disease, invasive, group A	1,205
Encophantio.	eastern equine*	1	Streptococcal toxic-shock syndrome*	43
	St. Louis*	I -	Syphilis, congenital [¶]	38
	western equine*	I .	Tetanus	8
Ehrlichiosis	human granulocytic (HGE)*	26	Toxic-shock syndrome	52
Lillioniosis	human monocytic (HME)*	3	Trichinosis	4
Hansen diseas		14	Typhoid fever	103
Hantavirus pulmonary syndrome*†		4	Yellow fever	105
	emic syndrome, postdiarrheal*	31	1 GHOW 16 VOI	

^{-:} No reported cases.

^{*}Not notifiable in all states.

† Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID).

† Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update April 30, 2000.

Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending May 20, 2000, and May 22, 1999 (20th Week)

							Escherichia coli O157:H7*				
ŀ	Cum.	Cum.	Chlan Cum.	nydia [†] Cum.	Cryptosı Cum.	cum.	NET Cum.	Cum.	PH Cum.	LIS Cum.	
Reporting Area UNITED STATES	2000⁵	1999 16,929	2000 210,632	1999	2000 422	1999 616	2000 587	1999 484	2000 357	1999 416	
NEW ENGLAND Maine N.H. Vt.	13,355 802 14 11 2	895 15 25 6	8,247 516 399 202	255,327 8,058 276 409 197	21 5 2 9	32 4 4 6	56 4 5 2	78 4 8 8	56 3 4 2	72 - 10 1	
Mass. R.I. Conn.	535 34 206	614 52 183	3,903 906 2,321	3,465 892 2,819	3 2	15 - 3	23 22	35 4 19	26 - 21	32 6 23	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	3,280 186 1,943 703 448	4,308 529 2,108 846 825	12,365 N 2,188 2,337 7,840	30,219 N 14,560 4,844 10,815	38 28 5 1 4	142 39 84 11 8	72 68 3 1 N	33 25 2 6 N	53 40 - 8 5	22 2 - 20	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	1,310 194 100 809 153 54	1,142 186 146 505 248 57	35,606 8,300 4,425 10,099 9,245 3,537	39,727 11,801 4,525 10,893 8,495 4,013	84 19 7 4 14 40	110 16 8 17 16 53	102 20 19 30 16 17	89 33 14 23 19 N	35 11 9 - 11 4	70 22 11 18 13 6	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	299 55 26 139 - 3 20 56	298 45 37 105 4 11 24 72	12,545 2,319 1,675 4,764 61 664 1,049 2,013	14,728 2,969 1,615 5,392 352 647 1,365 2,388	35 4 11 8 2 3 5 2	35 13 7 4 3 2 5	110 29 18 37 6 2 11	85 22 9 8 3 3 33 7	65 30 4 17 4 2 5	84 23 3 10 2 5 41	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	3,641 65 392 264 278 21 195 294 357 1,775	4,706 50 561 161 263 24 358 473 588 2,228	44,205 1,143 4,515 1,280 5,940 753 7,913 3,508 7,016 12,137	54,819 1,104 5,184 N 5,542 715 8,903 7,796 13,865 11,710	86 2 5 - 3 - 8 - 50 18	108 - 6 4 6 - 1 - - - - - 24	53 - 8 - 12 2 9 3 5 14	54 3 4 - 15 1 10 6 3 12	26 - 1 U 10 2 2 1 5	37 - - U 12 1 10 5 U	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	639 80 287 169 103	713 127 312 112 162	18,770 3,084 5,515 5,947 4,224	17,073 2,952 5,471 3,828 4,822	19 1 4 8 6	6 1 3 1	31 10 14 1 6	32 8 12 7 5	21 8 11 - 2	27 7 11 8 1	
W.S. CENTRAL Ark. La. Okla. Tex.	1,128 69 232 65 762	2,043 69 378 55 1,541	32,164 1,978 7,212 3,297 19,677	34,192 2,196 5,509 3,271 23,216	12 1 - 2 9	46 - 19 1 26	23 4 - 7 12	24 5 3 4 12	37 3 8 3 23	28 4 5 5 14	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	477 6 9 2 99 50 165 52 94	622 4 8 3 143 37 270 61 96	12,045 591 731 302 1,862 1,687 4,899 966 1,007	13,123 512 680 302 2,754 1,880 4,949 801 1,245	32 4 3 2 9 1 3 8 2	29 3 2 - 4 11 7 N 2	55 9 7 3 19 2 13 1	37 3 1 2 14 2 7 6 2	23 - - 2 7 2 11 1	25 3 3 5 1 4 7 2	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,779 202 47 1,476 5 49	2,202 115 50 1,989 6 42	34,685 4,830 1,799 26,413 974 669	43,388 4,679 2,400 34,332 750 1,227	95 N 3 92 -	108 N 10 98 -	85 18 12 50 1 4	52 13 13 25 - 1	41 22 14 - 5	51 21 12 17 - 1	
Guam P.R. V.I. Amer. Samoa C.N.M.I.	13 284 18 -	1 583 13 -	142 - - - -	181 U U U U	- - - -	- U U U	N 2 - -	N 8 U U U	U U U U	U U U U	

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.

*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

† Chlamydia refers to genital infections caused by *C. trachomatis*. Totals reported to the Division of STD Prevention, NCHSTP.

† Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update April 30, 2000.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending May 20, 2000, and May 22, 1999 (20th Week)

	weeks ending May 20, 2000, and May 22, 1999 (20th Week)											
	Gond	orrhea		atitis C; A, Non-B	Legion	iellosis		yme sease				
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999				
UNITED STATES	111,035	134,634	999	1,456	236	328	1,242	2,019				
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	2,238 32 35 20 1,017 233 901	2,538 22 28 24 990 228 1,246	23 - - 3 18 2	7 1 - 2 1 3	16 2 2 - 8 1 3	22 3 3 3 5 2 6	217 - 26 1 97 - 93	477 1 - 108 16 352				
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	8,172 2,252 824 1,282 3,814	16,173 2,325 6,115 2,808 4,925	22 22 - -	53 26 - - 27	43 20 - - 23	90 24 11 6 49	772 371 4 - 397	1,104 381 32 221 470				
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	22,212 4,823 2,020 7,173 6,680 1,516	23,858 6,326 2,500 7,713 5,739 1,580	93 3 1 6 83	833 - - 21 288 524	62 30 13 4 10 5	96 29 8 12 28 19	12 10 1 1 U	86 14 3 3 1 65				
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	5,389 932 358 2,812 4 96 349	6,154 1,112 361 3,012 35 61 616	244 1 1 222 - - 3	62 2 - 57 - - 3	17 1 3 10 - 1	16 1 5 7 - 1 2	47 13 1 9 -	39 8 3 19 1 -				
Kans.	838	957	17	-	2	-	24	4				
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	32,230 636 3,135 899 3,843 227 6,648 3,980 4,462 8,400	40,624 661 4,736 2,472 3,729 244 7,605 4,093 8,877 8,207	42 - 5 - 1 4 12 - - 20	85 - 23 - 8 11 20 12 1	50 4 14 3 N 6 2 3 18	36 2 4 - 9 N 7 6 - 8	154 12 103 - 14 6 8 1 -	215 12 160 1 11 4 25 1				
E.S. CENTRAL Ky. Tenn. Ala. Miss.	13,272 1,279 4,208 4,456 3,329	13,283 1,275 4,223 3,659 4,126	167 16 36 6 109	104 5 38 1 60	7 5 1 1	15 7 6 2	4 - 3 1 -	29 2 13 6 8				
W.S. CENTRAL Ark. La. Okla. Tex.	16,815 1,065 5,030 1,450 9,270	19,189 1,032 4,678 1,660 11,819	260 3 162 2 93	176 9 116 3 48	4 - 2 1 1	1 - 1 -	1 - 1 -	6 - 3 2 1				
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	3,848 20 34 25 1,268 367 1,610 105 419	3,581 17 34 11 835 328 1,810 81	85 1 - 54 12 5 10 - 3	80 4 30 11 13 14 2	15 - 1 1 7 1 2 3	24 - - - 4 1 3 10 6	1	4 - - 1 - 1 1				
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	6,859 847 216 5,594 119 83	9,234 828 346 7,758 134 168	63 8 15 40 -	56 5 7 44 -	22 8 N 14 -	28 7 N 20 1	34 - 2 32 - N	59 1 3 55 N				
Guam P.R. V.I. Amer. Samoa C.N.M.I.	170 - - -	27 144 U U U	- 1 - - -	- U U U	- - - -	- U U U	N - - -	N U U U				

N: Not notifiable.

U: Unavailable.

-: No reported cases.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending May 20, 2000, and May 22, 1999 (20th Week)

	WCCKS	maing ivi	ay 20, 20	oo, and iv	Salmonellosis*						
	Mal	aria	Rahie	s, Animal	NF.	TSS		ILIS			
Poporting Area	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.			
Reporting Area UNITED STATES	2000 328	1999 428	2000 1,857	1999 2,188	2000 9,150	1999 10,157	2000 6,060	1999 9,058			
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	12 2 1 2 3 2 2	16 1 - 1 6 - 8	240 59 3 16 83 6 73	341 60 24 53 76 40 88	584 50 44 43 328 25 94	573 40 29 23 332 32 117	578 25 43 44 329 36 101	605 25 29 25 344 44 138			
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	44 19 15 4 6	123 29 56 27 11	356 255 U 57 44	403 269 U 79 55	1,153 314 271 322 246	1,367 292 395 330 350	1,137 349 402 215 171	1,076 323 407 311 35			
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	32 4 2 14 10 2	51 8 7 23 9 4	17 4 - - 13 -	25 8 - 17 -	1,316 324 164 418 236 174	1,540 297 131 480 338 294	768 259 142 1 275 91	1,361 262 129 493 321 156			
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	15 4 - 1 2 - 2 6	15 2 5 7 - - 1	195 30 30 5 54 40 -	292 38 46 11 60 84 1 52	555 73 76 222 14 25 53 92	625 170 63 199 11 26 67 89	588 185 25 220 22 24 37 75	699 223 58 237 21 36 51 73			
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	93 2 35 2 20 - 9 1 4 20	102 32 9 20 1 9 - 7 24	793 13 154 - 208 48 175 51 91 53	782 23 172 - 187 45 168 57 61 69	1,754 32 251 1 224 47 252 139 292 516	1,803 41 248 34 218 31 330 95 307 499	1,026 30 223 U 184 33 155 113 282 6	1,608 50 270 U 194 29 335 110 444			
E.S. CENTRAL Ky. Tenn. Ala. Miss.	14 2 5 6 1	9 2 4 3	70 10 41 19	106 20 37 49	465 98 120 151 96	543 125 140 158 120	307 56 144 91 16	366 88 148 112 18			
W.S. CENTRAL Ark. La. Okla. Tex.	4 1 2 1	11 2 7 1 1	29 - - 29 -	46 - - 46 -	711 102 59 94 456	1,138 110 137 108 783	644 22 79 73 470	742 76 156 73 437			
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	18 1 - 10 - 2 3 2	18 2 1 - 7 2 4 1	71 23 - 22 - 4 21 1	71 25 - 26 1 - 19	928 38 45 18 281 71 253 138 84	888 18 32 9 285 100 260 118 66	641 - 14 246 59 197 125	827 1 37 13 290 102 199 132 53			
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	96 8 19 67 - 2	83 5 9 64 - 5	86 - - 71 15 -	122 - 1 116 5	1,684 143 117 1,337 23 64	1,680 140 138 1,278 15 109	371 157 145 - 16 53	1,774 255 174 1,238 7 100			
Guam P.R. V.I. Amer. Samoa C.N.M.I.	- - - -	- U U U	- 16 - - -	35 U U U	- 24 - - -	20 169 U U U	U U U U	U U U U			

N: Not notifiable. U: Unavailable. -: No reported cases.
*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending May 20, 2000, and May 22, 1999 (20th Week)

	weeks ending May 20, 2000, and May 22, 1999 (20th Week)										
	NET	Shige SS		PHLIS		philis k Secondary)	Tubei	rculosis			
Reporting Area	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.			
UNITED STATES	2000 5,369	1999 4,883	2000 2,489	1999 2,654	2000 2,276	1999 2,565	2000 3,631	1999 [†] 5,277			
NEW ENGLAND	106	126	89	113	26	24	134	130			
Maine N.H.	4 1	2 6	- 4	6	-	-	2 2	6 1			
Vt. Mass.	i 71	4 77	<u>-</u> 57	3 69	22	1 14	- - 88	<u>.</u> 62			
R.I.	9	12	8	9	1	1	12	16			
Conn. MID. ATLANTIC	20 690	25 358	20 493	26 191	3 74	8 114	30 813	45 866			
Upstate N.Y.	326	76	136	26	7	9	88	111			
N.Y. City N.J.	283 38	123 102	264 61	87 76	23 14	46 29	464 195	430 178			
Pa.	43	57	32	2	30	30	66	147			
E.N. CENTRAL Ohio	943 78	806 228	325 45	408 46	464 29	409 35	454 94	526 75			
Ind. III.	234 274	30 299	29 2	11 258	181 115	122 167	22 253	41 266			
Mich.	287 70	121	234 15	78 15	119 20	70 15	51 34	111			
Wis. W.N. CENTRAL	70 435	128 298	260	234	20 31	15 57	34 172	33 180			
Minn.	51	3 8	93	44	2	6	61	75			
lowa Mo.	108 226	4 211	22 119	7 153	10 14	4 40	13 68	14 64			
N. Dak. S. Dak.	2 2	2 7	1 -	2 4	-	-	9	1 3			
Nebr. Kans.	19 27	22 14	9 16	11 13	2	4 3	6 15	8 15			
S. ATLANTIC	748	784	154	201	759	903	727	1,009			
Del. Md.	5 37	7 48	3 10	2 10	2 119	2 179	- 86	11 89			
D.C.	49	24 28	Ü 35	Ü 9	22 53	46 63	2 57	17 83			
Va. W. Va.	2	4	2	2	1	2	15	19			
N.C. S.C.	44 18	77 36	16 28	43 15	230 76	207 107	112 30	153 131			
Ga. Fla.	90 503	83 477	28 32	30 90	116 140	165 132	137 288	205 301			
E.S. CENTRAL	276	421	191	245	362	457	250	321			
Ky. Tenn.	47 154	45 293	31 148	33 190	37 229	44 238	42 102	42 99			
Ala. Miss.	14 61	46 37	9	21 1	44 52	116 59	106	120 60			
W.S. CENTRAL	638	1,049	540	333	314	387	115	800			
Ark. La.	77 54	41 67	3 38	21 47	44 77	27 91	72 1	56 U			
Okla. Tex.	14 493	201 740	8 491	61 204	68 125	89 180	42	41 703			
MOUNTAIN	367	268	153	154	82	77	145	162			
Mont. Idaho	3 28	6 4	-	3	-	-	4 3	5			
Wyo.	1	2 45	2 30	1	1	-	-	1			
Colo. N. Mex.	63 38	37	20	33 21	2 11	1 5	13 19	U 21			
Ariz. Utah	143 31	142 17	66 35	72 18	66	68 1	66 12	87 16			
Nev.	60	15	-	6	2	2	28	32			
PACIFIC Wash.	1,166 229	773 37	284 222	775 47	164 23	137 28	821 <i>7</i> 2	1,283 57			
Oreg. Calif.	87 827	27 688	51	26 683	2 139	2 105	6 677	39 1,101			
Alaska	7	-	3	-	-	1	2 8	25			
Hawaii Guam	16	21 4	8 U	19 U	-	1	38	61			
P.R.	1	32 U	U	U	49	- 78 U	-	73 U			
V.I. Amer. Samoa	-	U	U	U U	-	U	-	U			
C.N.M.I.	-	U	U	U	-	U	-	U			

N: Not notifiable. U: Unavailable. -: No reported cases.
*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

†Cumulative reports of provisional tuberculosis cases for 1999 are unavailable ("U") for some areas using the Tuberculosis Information System (TIMS).

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending May 20, 2000, and May 22, 1999 (20th Week)

	H. influ	ienzae,	Hepatitis (Viral), By Type					Measles (Rubeola)				
		sive	A		В		Indige	nous	Impo		Tota	I
Reporting Area	Cum. 2000†	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	2000	Cum. 2000	2000	Cum. 2000	Cum. 2000	Cum. 1999
UNITED STATES	472	482	4,254	7,421	2,107	2,544	-	12	-	4	16	51
NEW ENGLAND	32	36	93	83	20	59	-	-	-	-	-	9
Maine N.H.	1 6	4 6	6 11	2 7	4 8	- 5	-	-	-	-	-	- 1
Vt. Mass.	2 16	4 15	3 39	1 26	3 3	1 26	-	-	-	-	-	- 6
R.I.	1	- 7	1	9	2	11	-	-		-	-	-
Conn. MID. ATLANTIC	6 66	7 73	33 179	38 475	193	16 373	U	-	U	-	-	2 2
Upstate N.Y.	30	29	89	95	45	79	-	-	-	-	-	2
N.Y. City N.J.	14 18	23 20	90	127 62	148 -	120 53	-	-	-	-	-	-
Pa.	4	1	-	191	-	121	-	-	-	-	-	-
E.N. CENTRAL Ohio	62 26	73 25	541 125	1,362 315	243 40	229 42	-	3 2	-	-	3 2	1 -
Ind. III.	10 22	11 30	20 187	47 263	20 38	19	-	-	-	-	-	1
Mich.	4	7	196	698	144	149	-	1	-	-	1	-
Wis.	-	-	13	39	1	19	-	-	-	-	-	-
W.N. CENTRAL Minn.	19 7	22 12	503 97	305 25	200 7	111 16	-	1 -	-	-	1 -	-
Iowa Mo.	- 4	1 2	40 252	63 174	19 134	19 63	-	-	-	-	-	-
N. Dak. S. Dak.	1	- - 1		1 8	2	-	-	-	-	-	-	-
Nebr.	3	3	17	27	18	10	-	-	-	-	-	-
Kans.	4	3	97	7	20	3	-	1	-	-	1	-
S. ATLANTIC Del.	135 -	105	521 -	658 2	439 -	397 -	-	-	-	-	-	4
Md. D.C.	28 -	30 3	65 2	133 30	44 6	82 10	-	-	-	-	-	-
Va. W. Va.	27 4	10 3	60 37	54 9	57 4	39 11	-	-	-	-	-	3
N.C.	10	20	84	50	109	93	-	-	-	-	-	-
S.C. Ga.	6 39	2 25	15 67	11 193	3 67	35 45	-	-	-	-	-	-
Fla.	21	12	191	176	149	82	-	-	-	-	-	1
E.S. CENTRAL Ky.	25 9	35 5	139 18	175 32	122 32	186 13	-	-	-	-	-	2 2
Ténn. Ala.	13 3	17 11	21 26	75 32	27 20	82 46	-	-	-	-	-	-
Miss.	-	2	74	36	43	45	-	-	-	-	-	-
W.S. CENTRAL Ark.	26	35 1	746 76	2,040 18	249 40	396 31	-	-	-	-	-	3
La.	6	9	26	66	45	77	-	-	-	-	-	-
Okla. Tex.	19 1	23 2	130 514	227 1,729	46 118	46 242	-	-	-	-	-	3
MOUNTAIN	54	51	358	627	168	239	-	8	-	1	9	-
Mont. Idaho	2	1 1	1 13	12 24	3 4	15 12	-	-	-	-	-	-
Wyo. Colo.	- 11	1 6	6 68	3 108	- 35	4 37	-	- 1	-	- 1	2	-
N. Mex.	11	10	37	20	37	81	-	-	-	-	-	-
Ariz. Utah	25 4	27 4	179 <i>2</i> 9	386 23	64 8	52 14	-	3	-	-	3	-
Nev.	1	1	25	51	17	24	U	4	U	-	4	-
PACIFIC Wash.	53 3	52 1	1,174 112	1,696 101	473 22	554 21	-	-	-	3	3	30 5
Oreg. Calif.	14 22	18 28	91 966	118 1,467	37 406	46 475	-	-	-	3	3	10 15
Alaska	1	4	5	4	3	7	Ū	-	Ū	-	-	-
Hawaii Guam	13	1	-	6 2	5	5 2	U	-	U	-	-	1
P.R.	-	1	40	112	24	107	U	-	U	-	-	-
V.I. Amer. Samoa	-	U U	-	U U	-	U U	U U	-	U	-	-	U U
C.N.M.I.	-	U	-	U . No ron	-	U	U	-	U	-	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.
*For imported measles, cases include only those resulting from importation from other countries.
*Of 112 cases among children aged <5 years, serotype was reported for 47 and of those, 10 were type b.

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending May 20, 2000, and May 22, 1999 (20th Week)

			and ivi	ay 22, 1	999 (2	oth w	еек				
		gococcal ease		Mumps			Pertussis			Rubella	
Reporting Area	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999
UNITED STATES	966	1,107	8	157	158	57	1,698	2,327	4	48	64
NEW ENGLAND	56	58	-	2	3	9	428	225	-	5	7
Maine N.H.	3 4	4 9	-	-	1	-	11 54	45	-	1	-
Vt. Mass.	2 37	4 33	-	-	2	6 3	94 244	9 159	-	3	- 7
R.I. Conn.	3 7	2 6	Ū	1 1	-	Ū	7 18	3 9	Ū	- 1	-
MID. ATLANTIC	86	108	-	9	19	1	132	509	-	2	9
Upstate N.Y. N.Y. City	22 21	28 36	-	6	3 3	1	77 -	447 10	-	2	5 -
N.J. Pa.	21 22	18 26	-	- 3	1 12	-	- 55	13 39	-	-	1 3
E.N. CENTRAL	175	197	-	17	20	17	222	187	_	-	-
Ohio Ind.	36 22	73 22	-	 7 -	6 2	10 3	156 22	95 9	-	-	-
III.	43	55	-	3	4	-	18	39	-	-	-
Mich. Wis.	56 18	24 23	-	7 -	7 1	4	16 10	17 27	-	-	-
W.N. CENTRAL Minn.	77 3	117 26	-	10	6	9 4	75 40	66 18	-	2	26
lowa	15	23	-	4	1	-	11	14	-	-	2
Mo. N. Dak.	48 1	40 3	-	1 -	1 -	3 -	12 1	17 -	-	-	-
S. Dak. Nebr.	4 3	5 8	-	2	-	-	1 3	2 1	-	-	- 24
Kans.	3	12	-	3	1	2	7	14	-	2	-
S. ATLANTIC Del.	159 -	153 3	3	25 -	2 8	4 2	147 3	105 -	-	28	2
Md. D.C.	15	27 1	-	5	4 2	1	36	36	-	-	1
Va. W. Va.	28 4	22 3	-	4	8	-	13	13 1	-	-	-
N.C. S.C.	26 10	22 21	- 1	3 7	5 3	-	39 16	26 7	-	20 6	1
Ga.	26	29	-	2	-	1	19	12	-	-	-
Fla. E.S. CENTRAL	50 68	25 85	2 1	4 5	6 3	- 1	21 30	10 49	-	2 4	2
Ky.	13	16	-	-	-	-	16	12	-	1	-
Tenn. Ala.	32 19	31 21	1	2	1	1 -	5 8	25 10	-	3	2
Miss. W.S. CENTRAL	4 80	17 105	-	1 15	2 21	3	1 61	2 62	-	2	- 4
Ark.	6	20	-	1	-	1	9	4	-	-	-
La. Okla.	25 19	37 18	-	3	3 1	-	3 5	2	-		- -
Tex.	30 54	30	-	11 15	17	2 5	44 215	48	-	2	4
MOUNTAIN Mont.	1	78 1	4 -	15 1	9	-	315 6	255 1	-	1 -	12 -
ldaho Wyo.	6	8 3	-	1	-	-	37 -	89 2	-	-	-
Colo. N. Mex.	15 7	20 10	-	1 1	3 N	4	173 57	68 19	-	1 -	-
Ariz. Utah	16 7	26 5	3 1	3 5	- 5	1	33 6	45 29	-	-	10 1
Nev.	2	5	Ú	3	1	U	3	2	U	-	i
PACIFIC Wash.	211 22	206 28	-	59 3	49 1	8 6	288 103	869 435	4	4	2
Oreg. Calif.	27 155	38 131	N -	N 51	N 42	2	31 144	16 398	- 4	- 4	2
Alaska	3 4	5 4	- - U	4	42 1 5	- U	6 4	3	- U	-	-
Hawaii Guam	-	4 1	U	1 -	5 1	U	-	17 1	U	-	-
P.R. V.I.	2	7 U	Ü	-	Ü	Ü	-	7 U	Ü	-	Ū
Amer. Samoa	-	Ü	Ü	-	Ü	Ü	-	Ü	Ü	-	Ü
C.N.M.I.	-	U	U	-	U	U	-	U	U	-	U

N: Not notifiable.

U: Unavailable.

TABLE IV. Deaths in 122 U.S. cities,* week ending May 20, 2000 (20th Week)

					viay	20,	200	UU (20th Week)					_		
		All Cau	ises, By	Age (Ye	ears)		P&I⁺			All Cau	ses, By	Age (Y	ears)		P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass Waterbury, Conn.	. 26 30 45 27 12 ss. 20 . 40 53 6	429 103 25 21 27 31 17 9 17 29 43 37 27	29 5 3 2 13 7 2 1 8 3 2 9	33 14 1 2 1 - 3 1 2 2 3 1 2 2	11 5 - - 1 - 1 1 - 2 1	6 3 3	48 16 1 2 2 4 3 - 2 5 2	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, F Tampa, Fla. Washington, D.C Wilmington, Del	97 52 74 37 Fla. 76 239 C. 100	700 96 73 96 55 31 31 23 57 164 68	232 U 33 23 26 24 9 28 9 12 47 21	105 U 21 7 10 17 3 10 4 5 20 8	21 U 6 - 1 - 2 1 1 1 5 1 3	22 U 3 1 1 7 4 - 1 2 2	78 U 13 8 10 16 3 2 - 5 18 3
Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§ Jersey City, N.J. New York City, N.Y. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y.	62 2,097 40 U 78 32 35 43 35 4. 1,136 48 18 256 63 31 128	1,475 29 U 55 23 32 24 805 24 12 154 43 97 21 23 27 16 20 20	6 408 7 U 15 4 1 9 8 225 9 3 64 11 1 25 4 6 11 3	1 141 4 U 5 2 1 2 79 9 1 24 3 1 4	40 - U 2 2 - 2 - 7 3 - 9 2 - 1	33 - U 1 1 10 3 2 5 4 1 1 - 3 - U	9 101 1 U 6 1 2 3 - 41 2 - 14 3 1 10 6 2 6 2 1 U	E.S. CENTRAL Birmingham, Ala Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Al Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, T Dallas, Tex. El Paso, Tex. El Paso, Tex. Little Rock, Ark. New Orleans, La. San Antonio, Te: Shreveport, La. Tulsa, Okla.	nn. 79 79 70 201 Ula. 40 137 1,565 119 38 Fex. 56 210 98 413 77 99	525 124 60 52 47 130 29 83 1,021 86 32 38 121 39 99 259 49 145 43 76	158 32 14 17 16 37 7 35 307 18 5 10 45 21 87 12 16 37 10 30	69 18 5 4 22 12 13 13 8 1 5 25 9 4 47 9 1 14 3 10	15 1 4 2 6 0 2 6 3 1 1 17 4 12 9 1 2	18 4 - 1 1 6 U - 6 34 4 - 1 8 3 3 3 3 4 2 - 3	68 17 7 4 8 15 11 6 94 8 1 7 9 9 9 9 1 9 9 4 -
Yonkers, N.Y. E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, Ill. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Gary, Ind. Grand Rapids, Mi Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, Ill. Rockford, Ill. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansas City, Mo. Lincoln, Nebr. Minneapolis, Min Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	2,018 48 48 35 395 96 122 210 107 176 53 76 18 ch. 42 178 31 178 31 178 31 178 31 178 31 178 31 178 31 178 31 178 31 178 31 31 31 31 31 31 31 31 31 31 31 31 31	1,332 33 21 242 63 77 143 73 88 39 53 114 21 75 41 33 46 75 50 63 74 56 63 66 63 66 63 63 66	422 10 12 84 23 26 35 24 48 8 17 5 12 41 5 20 7 1 11 21 21 6 15 12 6 15 12 16 16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	158 4 2 41 91 13 6 23 5 5 1 1 3 3 3 4 2 5 2 3 5 5 5 40 - 7 7 11 2 3 3 1 5 3 8	37 	67 1 - 17 1 4 100 3 6 6 1 5 5 1 1 1 7 7 1 1 1 1 3 2 - 2 22 1 1 6 6 1 6 2 5	120223865169826-131423183 88182-162499	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Calif. Dos Angeles, Cal Pasadena, Calif. Portland, Oreg. Sacramento, Cal San Diego, Calif. San Francisco, C San Jose, Calif. Santa Cruz, Calif.	910 .M. U 38 olo. 73 106 234 25 169 32 tah 114 119 9 ii 75 if. 64 if. 409 iif. U 29 iif. 167 alif. U alif. U 126	615 28 48 48 169 21 100 16 77 88 981 6 U 8 5 45 286 9 0 124 30 80 44 84	177 U 3 13 29 48 2 40 8 16 18 270 1 13 9 86 4 24 U 26 U 42 2 27 11 23	74 9 6 11 2 17 7 8 10 8 6 28 1 11 U 8 8 10 2 11 11 14 4 8 4 8 8 10 2 8 11 11 11 11 11 11 11 11 11	26 U 2 3 2 2 2 6 1 8 2 24 U - 1 5 1 5 U 3 U 2 4 3 255	18 U 1 - 1 4 - 6 - 5 1 28 1 U - 1 3 4 4 1 1 3 U 7 7 U 3 - 4 - 1 1 248	62 U 1 5 5 20 3 11 - 9 8 106 1 U - 8 15 16 - 7 U 18 U 8 6 12 5 10 746

U: Unavailable. -:No reported cases.

*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. Pneumonia and influenza.

*Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

*Total includes unknown ages.

Contributors to the Production of the MMWR (Weekly) Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Jose Aponte
Paul Gangarosa, M.P.H.
Gerald Jones David Nitschke Carol A. Worsham

CDC Operations Team

Carol M. Knowles Deborah A. Adams Willie J. Anderson Patsy A. Hall Pearl Sharp Kathryn Snavely

Informatics

T. Demetri Vacalis, Ph.D.

Michele D. Renshaw Erica R. Shaver The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/ or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333: telephone (888) 232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.

Acting Deputy Director for Science and Public Health, Centers for Disease Control and Prevention Walter W. Williams, M.D., M.P.H. Acting Director, Epidemiology Program Office Barbara R. Holloway, M.P.H. Editor. *MMWR* Series

John W. Ward, M.D. Acting Managing Editor, MMWR (Weekly) Caran R. Wilbanks Writers-Editors, MMWR (Weekly) Jill Crane David C. Johnson Teresa F. Rutledge Desktop Publishing Lynda G. Cupell Morie M. Higgins

☆U.S. Government Printing Office: 2000-533-206/28014 Region IV